Hematology saw a mix of breakthroughs and setbacks in July 2026, with the FDA approving expanded access to gene therapies and new delivery methods for existing drugs. The industry is shifting toward more personalized treatments, though challenges remain in accessibility and long-term safety.
Expanding Access to Curative Therapies
The FDA approved exagamglogene autotemcel (Casgevy; Vertex Pharmaceuticals/CRISPR Therapeutics) for children as young as 2 years old with sickle cell disease or transfusion-dependent beta-thalassemia. This approval extends eligibility for CRISPR/Cas9 gene therapy to a much younger population, offering a chance to intervene before irreversible organ damage occurs. However, the treatment still requires stem cell mobilization, myeloablative conditioning, and specialized manufacturing at authorized centers.
Related: User account blocked after policy violation
Another significant shift involves the FDA approval of Tregzi (Orca Bio), a precision-engineered immunotherapy for matched-donor stem cell transplantation. The therapy separates donor cells into regulatory T cells, stem and progenitor cells, and conventional T cells to support recovery while reducing graft-versus-host disease. In clinical trials, approximately 78% of patients receiving Tregzi were alive and free from moderate-to-severe chronic GVHD at one year, compared to 38% with conventional transplants.
Wilate, a von Willebrand factor concentrate, is now approved for prophylaxis in children younger than 6 years with von Willebrand disease. This makes it the first such product indicated for all age groups and forms of the disorder. Clinical data showed an annualized bleeding rate of about 4.6 in young children, with most episodes requiring only a single infusion.
New Options for Bleeding Disorders and Myeloma
For patients with multiple myeloma, teclistamab-cqyv (Tecvayli) demonstrated major survival benefits in a phase 3 trial. The dual-targeting therapy reduced the risk of death by 62% compared to standard therapies, offering a potent option for patients who have already received multiple lines of treatment.
Related: User Blocked by Social Media Platform
Targeted Treatments Show Promise in Lymphomas
For relapsed or refractory multiple myeloma, the combination of teclistamab-cqyv (Tecvayli) and talquetamab-tgvs demonstrated major survival benefits in a phase 3 trial. The dual-targeting therapy reduced the risk of death by 62% compared to standard therapies, offering a potent option for patients who have already received multiple lines of treatment.
In chronic lymphocytic leukemia, the BTK inhibitor orelabrutinib outperformed traditional chemoimmunotherapy in a phase 3 trial. Patients treated with orelabrutinib had a median progression-free survival of about 21.4 months, compared to 19.4 months with the standard combination, representing a significant reduction in disease progression risk. This supports a growing trend toward chemotherapy-free approaches in early-line CLL treatment.
Long-term follow-up of early CAR T-cell therapy studies indicates that a single infusion can produce decade-long disease control in a subset of patients with B-cell lymphomas. At a 10-year median follow-up, roughly half of patients with follicular lymphoma remained in remission, suggesting that cellular therapies may offer potential cures for a specific group of individuals.
Related: User Account Blocked by Social Media Platform
Setbacks in Transplant Complications
A major setback occurred in the field of transplant-associated thrombotic microangiopathy (TA-TMA). Ravulizumab-cwvz (Ultomiris) failed to meet its primary end point in a phase 3 trial for adults and adolescents undergoing hematopoietic stem cell transplantation. While the study showed a numerical trend favoring the drug, it did not achieve statistical significance, leaving a critical gap in treatment options for this condition.
In another area of unmet need, the ASH/ISTH updated clinical practice guidance for anticoagulant prophylaxis in pediatric patients. The recommendations stress that prophylaxis should be individualized based on bleeding and thrombosis risks, as evidence from adult populations does not always apply to children. The guidance also highlights the importance of sex-specific research, following a global commission report that identified significant inequities in hematologic care for women and girls.
